NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,430.30 +12.90 (+0.53%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,842.99 +2,700.71 (+5.18%)
Dynavax Technologies Corporation (DVAX)
After hours:
| Previous close | 11.11 |
| Open | 11.20 |
| Bid | 11.37 x 500 |
| Ask | 11.41 x 500 |
| Day's range | 11.07 - 11.47 |
| 52-week range | 10.48 - 15.15 |
| Volume | |
| Avg. volume | 2,087,022 |
| Market cap | 1.491B |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | 162.71 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the sBLA, stating that the application did not provide sufficient data to support the full evaluation of effectiveness
- PR Newswire
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
- PR Newswire
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
